Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
FDA approves turoctocog alfa pegol for hemophilia A
The product won’t be available before 2020.
News
Researchers characterize new subtype of high-grade DLBCL
Patients with this subtype had distinct molecular features and poor prognosis.
News
EC approves BV plus AVD for Hodgkin lymphoma
The approval for this indication is supported by the phase 3 ECHELON-1 trial.
News
Few DLBCL patients benefit from nivolumab
Just 10 of 121 patients responded to nivolumab in a phase 2 trial and researchers aren’t sure why this particular group of patients responded.
News
EC approves dasatinib plus chemo for kids with Ph+ ALL
Dasatinib will be available in tablet form and as a powder for oral suspension.
News
New ASBMT president takes the helm, more hem/onc appointments
Dr. Navneet Majhail will assume the office of ASBMT president at the end of February.
Video
Increased risk of second cancers in mycosis fungoides
LA JOLLA, CALIF. – Researchers found the risk of second malignancy was highest among MF patients aged 30 to 50 years and patients who had tumor...
Video
Cobomarsen shows early promise for treating ATLL
LA JOLLA, CALIF. – A small number of patients experienced disease stabilization or regression on cobomarsen.
News
FDA approves caplacizumab for aTTP
The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia...
Video
Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
LA JOLLA, CALIF. – Some CTCL patients experienced relief from itching after just one pill.
Video
Combo emerges as bridge to transplant in rel/ref PTCL
LA JOLLA, CALIF. – Researchers plan to expand the duvelisib plus romidepsin arm to better understand the occurrence of transaminitis and assess...
News
FDA grants BI-1206 orphan designation for MCL
BI-1206 is under investigation in a phase 1/2a study.
Video
Applying ECHELON-2 results to clinical practice
LA JOLLA, CALIF. – At the annual T-cell Lymphoma Forum, physicians discussed how the ECHELON-2 trial may affect clinical practice.
News
IPH4102 on fast track for Sézary syndrome
The designation is based on results from a phase 1 trial of 35 patients.